Tagraxofusp
Tagraxofusp is a CD123-directed cytotoxin consisting of recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin fragment, targeting CD123 (the IL-3 receptor alpha subunit) overexpressed on blastic plasmacytoid dendritic cell neoplasm (BPDCN) cells and AML blasts. After IL-3-mediated CD123 binding and cellular internalization, the diphtheria toxin moiety inhibits protein synthesis by ADP-ribosylating elongation factor 2 (EF-2), causing cell death. It is the first therapy approved specifically for BPDCN.
Áreas terapéuticas
Mecanismo de acción
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Tagraxofusp is a CD123-directed cytotoxin consisting of recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin fragment, targeting CD123 (the IL-3 receptor alpha subunit) overexpressed on blastic plasmacytoid dendritic cell neoplasm (BPDCN) cells and AML blasts. After IL-3-mediated CD123 binding and cellular internalization, the diphtheria toxin moiety inhibits protein synthesis by ADP-ribosylating elongation factor 2 (EF-2), causing cell death. It is the first therapy approved specifically for BPDCN.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Tagraxofusp is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297573. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tagraxofusp"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tagraxofusp/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tagraxofusp/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tagraxofusp/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tagraxofusp"></drugfyi-drug>